Inhibition of viral gene expression
AssigneeUniversity of the Witwatersrand, Johannesburg
InventorsPatrick Arbuthnot, Justin Hean, Abdullah Ely, Musa Marimani, Jolanta Brzezinska, Jennifer D'Onofrio, Maximilian C.R. Buff, Joachim W. Engels, Stefan Bernhardt
Life of this patent
Estimating the term…
Abstract
This invention relates to modified short interfering RNA (siRNA) nucleic acid molecules, particularly siRNA's which have been modified by the addition of a 2-0-guanidinopropyl (GP) modified nucleoside. In particular the invention relates to modified siRNAs which are capable of silencing target sequences, methods of treating and preventing infection by using the siRNAs, medicaments containing the siRNAs and use of the siRNAs.
Claims19
A modified short interfering RNA (siRNA) nucleic acid molecule, comprising a sense strand and an antisense strand, wherein at least one nucleotide in the sense strand or at least one nucleotide in the antisense strand is derived from a 2′-0-guanidinopropyl (GP) modified nucleoside, and wherein the modified siRNA nucleic acid molecule is capable of silencing the expression of a target sequence.
A method of treatment or prevention of a viral infection, the method comprising administering a therapeutic amount of a modified siRNA nucleic acid molecule comprising
- a sense strand and an antisense strand, wherein at least one nucleotide in the sense strand or at least one nucleotide in the antisense strand is a 2′-0-guanidinopropyl (GP) modified nucleoside, and wherein the modified siRNA nucleic acid molecule is capable of silencing the expression of a target sequence;
- and a pharmaceutically acceptable adjuvant and/or carrier to a subject in need thereof.
19-26. (canceled)
Dependencies are inferred from the claim text.